918 related articles for article (PubMed ID: 16507884)
1. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.
Pacher P; Nivorozhkin A; Szabó C
Pharmacol Rev; 2006 Mar; 58(1):87-114. PubMed ID: 16507884
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Xanthine Oxidase: Scaffold Diversity and Structure-Based Drug Design.
Luna G; Dolzhenko AV; Mancera RL
ChemMedChem; 2019 Apr; 14(7):714-743. PubMed ID: 30740924
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol, xanthine oxidase, and cardiac ischemia.
Lee BE; Toledo AH; Anaya-Prado R; Roach RR; Toledo-Pereyra LH
J Investig Med; 2009 Dec; 57(8):902-9. PubMed ID: 19794315
[TBL] [Abstract][Full Text] [Related]
4. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
5. Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage.
Das DK; Engelman RM; Clement R; Otani H; Prasad MR; Rao PS
Biochem Biophys Res Commun; 1987 Oct; 148(1):314-9. PubMed ID: 2823807
[TBL] [Abstract][Full Text] [Related]
6. The role of urate and xanthine oxidase inhibitors in cardiovascular disease.
George J; Struthers AD
Cardiovasc Ther; 2008; 26(1):59-64. PubMed ID: 18466421
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol as a therapeutic option in cardiovascular disease.
Okafor ON; Farrington K; Gorog DA
Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Lü JM; Yao Q; Chen C
Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
Gao J; Liu X; Zhang B; Mao Q; Zhang Z; Zou Q; Dai X; Wang S
Eur J Med Chem; 2020 Mar; 190():112077. PubMed ID: 32014678
[TBL] [Abstract][Full Text] [Related]
10. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR;
Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261
[TBL] [Abstract][Full Text] [Related]
12. Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Zhao L; Roche BM; Wessale JL; Kijtawornrat A; Lolly JL; Shemanski D; Hamlin RL
Life Sci; 2008 Feb; 82(9-10):495-502. PubMed ID: 18215719
[TBL] [Abstract][Full Text] [Related]
13. A new sensitive and quantitative chemiluminescent assay to monitor intracellular xanthine oxidase activity for rapid screening of inhibitors in living endothelial cells.
Caliceti C; Calabria D; Roda A
Anal Bioanal Chem; 2016 Dec; 408(30):8755-8760. PubMed ID: 27392750
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
15. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
16. Results of and further prevention of hypoxic fetal brain damage by inhibition of xanthine oxidase enzyme with allopurinol.
Boda D
J Perinat Med; 2011 Jul; 39(4):441-4. PubMed ID: 21410409
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease.
Landmesser U; Spiekermann S; Preuss C; Sorrentino S; Fischer D; Manes C; Mueller M; Drexler H
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):943-8. PubMed ID: 17234726
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
19. Hydralazine improves ischemia-induced neovasculogenesis via xanthine-oxidase inhibition in chronic renal insufficiency.
Chang TT; Chen JW
Pharmacol Res; 2020 Jan; 151():104509. PubMed ID: 31678640
[TBL] [Abstract][Full Text] [Related]
20. Superoxide radical production by allopurinol and xanthine oxidase.
Galbusera C; Orth P; Fedida D; Spector T
Biochem Pharmacol; 2006 Jun; 71(12):1747-52. PubMed ID: 16650385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
